Phase I or randomized phase II study of second line therapy with irinotecan and cetuximab with or without RAD001 [everolimus], an oral mTOR [mammalian target of rapamycin] inhibitor for patients with metastatic colorectal cancer: Hoosier Oncology Group GI05-102.

Trial Profile

Phase I or randomized phase II study of second line therapy with irinotecan and cetuximab with or without RAD001 [everolimus], an oral mTOR [mammalian target of rapamycin] inhibitor for patients with metastatic colorectal cancer: Hoosier Oncology Group GI05-102.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Everolimus (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 17 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 14 Mar 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2013 to 1 Dec 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top